---
layout: default
title: Fluocinonide
parent: Model Prediction Only (L5)
nav_order: 147
evidence_level: L5
indication_count: 7
---

# Fluocinonide
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **7** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Fluocinonide: From Inflammatory Skin Conditions to Alopecia Mucinosa

## One-Sentence Summary

Fluocinonide is a high-potency topical corticosteroid, originally used for inflammatory skin diseases such as atopic eczema, contact dermatitis, seborrheic dermatitis and discoid lupus erythematosus.
The TxGNN model predicts it may be effective for **alopecia mucinosa** (top-ranked prediction), but **no clinical trials and no publications** currently support this specific pair, so the evidence rests on the model prediction alone.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Inflammatory skin diseases (e.g., atopic eczema, contact dermatitis, seborrheic dermatitis, discoid lupus erythematosus). The Philippines registration record has no approved indication text. |
| Predicted New Indication | Alopecia mucinosa |
| TxGNN Prediction Score | 99.61% |
| Evidence Level | L5 |
| Philippines Market Status | Cancelled only |
| Number of Registrations | 1 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, fluocinonide is a high-potency topical corticosteroid with anti-inflammatory and immunosuppressive effects. Its efficacy in inflammatory skin diseases is established, and mechanistically it may be applicable to alopecia mucinosa.

Alopecia mucinosa (follicular mucinosis) is an inflammatory follicular disorder. A glucocorticoid effect is therefore biologically plausible, and topical corticosteroids are used in clinical practice for localized lesions. The original indications (eczema, dermatitis, discoid lupus) are also inflammatory skin conditions, which supports the link.

However, the data compiled for this report contain no trials or literature for this drug-indication pair. The high score is a computational prediction only.

**Other predicted indications (all with a similar score of about 99.5%):**

| Predicted Indication | Evidence Level | Comment |
|------|------|------|
| Telogen effluvium | L5 | Usually non-inflammatory shedding; no clear mechanistic rationale |
| Alopecia areata | L4 | Autoimmune; corticosteroids are a plausible drug class, but the evidence is indirect (see below) |
| Folliculitis decalvans (Quinquaud) | L5 | Antibiotic-based first-line care; corticosteroid at most an adjunct |
| Hereditary hypotrichosis with recurrent skin vesicles | L5 | Rare genetic disorder; weak link |
| Alopecia antibody deficiency | L5 | Immune deficiency syndrome; weak rationale and questionable risk |
| Alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome | L5 | Rare genetic syndrome; no plausible link |

Among these, alopecia areata has the most supportive class-level rationale, but no fluocinonide-specific efficacy data. Several of the others appear to reflect shared alopecia phenotypes in the knowledge graph.

---

## Clinical Trial Evidence

Currently no related clinical trials are registered for alopecia mucinosa.

For the third-ranked prediction, alopecia areata, one loosely related trial was found:

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT04207931](https://clinicaltrials.gov/study/NCT04207931) | Phase 4 | Recruiting | 250 | Multicenter prospective study comparing treatment outcomes by before/after photos in central centrifugal cicatricial alopecia (CCCA), a different scarring alopecia. The data do not confirm fluocinonide is the studied drug, so it gives no direct evidence. |

---

## Literature Evidence

Currently no related literature is available for alopecia mucinosa.

For alopecia areata, one publication was found:

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [15692503](https://pubmed.ncbi.nlm.nih.gov/15692503/) | 2005 | Case report | Journal of the American Academy of Dermatology | Four cases of congenital alopecia areata followed for 3–5 years, with prolonged quiescent periods. Treatments included minoxidil 2% and various topical agents. It is not specific to fluocinonide efficacy. |

---

## Philippines Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| PNF-0196 | Fluocinonide | Not recorded | Not recorded (registration status: cancelled) |

The only registration is cancelled, so there is currently no valid marketed fluocinonide product in the Philippines according to the data compiled.

---

## Safety Considerations

Package insert warnings and contraindications were not available for this report. Please refer to the package insert for safety information.

Additional signals from the knowledge graph (these are database associations, not label text):
- **Disease associations flagged as contraindications:** hyperglycemia, diabetes mellitus, diabetic ketoacidosis, Cushing syndrome and adrenal gland hyperfunction, hypopituitarism and other pituitary hormone deficiencies (including Sheehan syndrome), growth hormone deficiency, hypogonadotropic hypogonadism (including Kallmann syndrome), and thymus gland disease. These are consistent with the systemic effects of corticosteroids and should be verified against the official label.
- **Drug interactions:** 64 interactions were identified, but severity levels are unclassified. Examples include other corticosteroids (triamcinolone, prednisone, budesonide, dexamethasone, fluticasone), cyclosporine, clopidogrel, acetylsalicylic acid, ibuprofen, and clotrimazole. Clinical significance needs to be confirmed.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top prediction (alopecia mucinosa) is supported only by the TxGNN score and a plausible class-level mechanism. There are no trials or literature (evidence level L5), the only Philippines registration is cancelled, and package insert safety data are missing.

**To proceed, the following is needed:**
- A literature review of topical corticosteroid use in follicular mucinosis, to find case series or observational data
- Mechanism of action data (e.g., from DrugBank)
- The Philippines package insert (warnings and contraindications), and confirmation of whether any topical fluocinonide product is currently available or can be re-registered
- Route and formulation compatibility (topical vs. intralesional) for scalp or hair-bearing skin
- A review of the DDI severity levels and of the systemic absorption risk, particularly in patients with diabetes or endocrine disorders
- If a hair-loss indication is pursued, alopecia areata is the more promising candidate for a focused evidence search, given its established corticosteroid class rationale
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

